search
Penn Medicine
Trends
- 1OpenEvidence partners with Anthropic and Penn Medicine for AI expansion▼OpenEvidence partners with Anthropic, Penn Medicine to expand physician access to AI across Africa and Asia
OpenEvidence has announced a partnership with Anthropic and Penn Medicine to expand physician access to its AI-powered clinical decision support tools across Africa and Asia. The collaboration aims to bring AI assistance to doctors in regions with limited medical resources, marking a notable step in extending US-developed health AI to global markets.
- 2
Doctors are reporting severe withdrawal cases linked to medetomidine, a veterinary sedative increasingly appearing in the illicit drug supply. Penn Medicine highlighted the trend, suggesting growing use of the drug alongside or in place of other sedatives like xylazine. Clinicians say withdrawal from medetomidine can be intense and hard to treat, raising concern about a new and poorly understood substance complicating the overdose crisis.
- 3Penn Medicine and IBA Launch Proton Therapy Joint Venture▼Penn Medicine, IBA Form Joint Venture to Advance Proton Therapy, Radiation Oncology
Penn Medicine and Belgian medical technology company IBA have formed a joint venture aimed at advancing proton therapy and radiation oncology. The partnership will combine Penn Medicine's clinical expertise with IBA's technology to develop and expand proton therapy treatments for cancer patients.
- 4Penn Medicine plans new surgery centers in Delaware▼Penn Medicine expands Delaware push with planned surgery centers
Penn Medicine is expanding its presence in Delaware with plans to open new surgery centers. The announcement, reported by the Delaware Business Times, signals the health system's continued push into the state's healthcare market, adding outpatient surgical capacity for Delaware residents who often travel to Philadelphia for care.